RXRX Stock Analysis: Buy, Sell, or Hold?
RXRX - Recursion Pharmaceuticals, Inc. Class A Common Stock
$3.30
-0.26 (-7.30%)
▼
5d:
-16.67%
30d:
+8.55%
90d:
+0.61%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 04, 2026
20d
Smart Money Distribution
None View Scanner →
Strength: 8.9/10
Get Alerted When RXRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called RXRX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RXRX is down 16.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RXRX is down 16.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RXRX is currently trading at $3.30, which is considered fair relative to its 30-day fair value range of $3.16 to $3.70.
Technical Outlook: Technically, RXRX is in a uptrend. The price is currently testing key support at $3.41. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.25 (+119.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RXRX is in a uptrend. The price is currently testing key support at $3.41. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.25 (+119.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.16 -
$3.70
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
Protect Your Profits
Holding RXRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.3%)
- BULLISH: Trading 119.7% below Wall St target ($7.25)
- WARNING: Recommendation downgraded due to -16.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.16 -
$3.70
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.41
Resistance Level
$4.09
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.51
Wall Street Target
$7.25
(+119.7%)
Revenue Growth (YoY)
-56.1%
Share & Embed Analysis
Last updated: July 13, 2026 11:33 PM ET
Data refreshes hourly during market hours. Next update: 12:33 AM
Data refreshes hourly during market hours. Next update: 12:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RXRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Blake Borgeson
SELL
30000 shares
2026-04-07
Ben R Taylor
SELL
7956 shares
2026-03-17
Najat Khan
SELL
28298 shares
2026-03-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
Advanced RXRX Option Strategies
Professional options setups generated by AI based on today's RXRX price and gamma walls.
